201 related articles for article (PubMed ID: 30168534)
1. The hepatocellular carcinoma market.
Dawkins J; Webster RM
Nat Rev Drug Discov; 2019 Jan; 18(1):13-14. PubMed ID: 30168534
[No Abstract] [Full Text] [Related]
2. Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma.
Gyawali B
J Natl Compr Canc Netw; 2019 Jun; 17(6):760-762. PubMed ID: 31200350
[No Abstract] [Full Text] [Related]
3. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
Armstrong SA; He AR
Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
[TBL] [Abstract][Full Text] [Related]
4. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth.
Crespo J; Andrade RJ
Rev Esp Enferm Dig; 2019 Oct; 111(10):727-730. PubMed ID: 31566408
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
Chen S; Cao Q; Wen W; Wang H
Cancer Lett; 2019 Sep; 460():1-9. PubMed ID: 31207320
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
Neureiter D; Stintzing S; Kiesslich T; Ocker M
World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
[TBL] [Abstract][Full Text] [Related]
7. Shifting paradigms in the systemic management of hepatocellular carcinoma.
Pinato DJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):883-885. PubMed ID: 32941832
[No Abstract] [Full Text] [Related]
8. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".
Li X; Liang P; Ye X
J Cancer Res Ther; 2019; 15(2):267-268. PubMed ID: 30964095
[No Abstract] [Full Text] [Related]
9. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
[No Abstract] [Full Text] [Related]
10. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
11. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
12. Immune oncology in hepatocellular carcinoma-hype and hope.
Wörns MA; Galle PR
Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
[No Abstract] [Full Text] [Related]
13. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
14. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
16. Baying for a flexible drug price.
Lancet; 2009 Nov; 374(9704):1794. PubMed ID: 19944844
[No Abstract] [Full Text] [Related]
17. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
18. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
Bouattour M; Rousseau B; Wassermann J; Payancé A; Huillard O
J Clin Oncol; 2015 Aug; 33(22):2484-5. PubMed ID: 26033820
[No Abstract] [Full Text] [Related]
19. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
20. Durable Complete Response of Brain Metastasis From Hepatocellular Carcinoma On Treatment With Nivolumab and Radiation Treatment.
Ye L; Zhang C; Seidensticker M; Mayerle J; Reiter FP; De Toni EN
Am J Gastroenterol; 2020 Dec; 115(12):2114-2116. PubMed ID: 32852335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
